Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies

Overall survival of patients with hepatocellular carcinoma (HCC) refractory to locoregional therapy is dismal, even following treatment with sorafenib, a multikinase inhibitor. To develop a more efficacious treatment, we undertook a feasibility study of personalized peptide vaccination (PPV) for HCC...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cancer Sci
Main Authors: Yutani, Shigeru, Shirahama, Takahisa, Muroya, Daisuke, Matsueda, Satoko, Yamaguchi, Rin, Morita, Michi, Shichijo, Shigeki, Yamada, Akira, Sasada, Tetsuro, Itoh, Kyogo
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5581512/
https://ncbi.nlm.nih.gov/pubmed/28622427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.13301
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares